Polymyxin B (Sulfate): Precision Antibiotic for Multidrug-Resistant Gram-Negative Bacteria

Executive Summary: Polymyxin B (sulfate) is a cationic polypeptide antibiotic derived from Bacillus polymyxa strains, with a primary composition of polymyxins B1 and B2. It exhibits potent, concentration-dependent bactericidal activity against major multidrug-resistant Gram-negative bacteria, including Pseudomonas aeruginosa (APExBIO, product page). Its mechanism involves disruption of the outer membrane, leading to rapid cell death. In immune assays, Polymyxin B is shown to upregulate dendritic cell maturation markers and activate ERK1/2 and NF-κB signaling pathways. Benchmark studies confirm efficacy in reducing bacterial load and improving survival in preclinical sepsis and bacteremia models (Sardar et al., 2025, DOI). Use is tempered by well-characterized nephrotoxicity and neurotoxicity risks at higher systemic exposures.

Biological Rationale

Gram-negative bacteria possess a protective outer membrane rich in lipopolysaccharides (LPS), conferring resistance to many antibiotics. Polymyxin B (sulfate) targets this membrane, making it vital for combating multidrug-resistant strains that evade standard therapies. It is especially critical in experimental and clinical scenarios involving Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae (related article). By compromising membrane integrity, Polymyxin B enables both direct bacterial killing and potentiation of host immune responses, especially in research evaluating LPS-mediated TLR4 signaling and immune checkpoint inhibitor (ICI) modulation (Sardar et al., 2025, DOI).

Mechanism of Action of Polymyxin B (sulfate)

Polymyxin B (sulfate) acts as a cationic detergent, interacting with the negatively charged LPS in the outer membrane of Gram-negative bacteria. This interaction displaces stabilizing divalent cations (Ca²⁺, Mg²⁺), increasing membrane permeability and resulting in leakage of intracellular contents and rapid cell lysis (APExBIO). In immune research contexts, Polymyxin B is also used to neutralize LPS in dendritic cell maturation assays, distinguishing direct bacterial effects from LPS-driven immune activation. Furthermore, exposure of human dendritic cells to Polymyxin B in vitro upregulates co-stimulatory molecules such as CD86 and HLA class I/II, activating signaling pathways including ERK1/2 and IκB-α/NF-κB (Sardar et al., 2025).

Evidence & Benchmarks

• Polymyxin B (sulfate) demonstrates bactericidal activity against multidrug-resistant Pseudomonas aeruginosa at concentrations ≥0.5 μg/mL in cation-adjusted Mueller Hinton broth (APExBIO, product page).
• In vitro, Polymyxin B promotes dendritic cell maturation, increasing CD86 and HLA class I/II expression after 24 h exposure at 2 μg/mL (Sardar et al., 2025, DOI).
• In mouse bacteremia models, intraperitoneal administration of Polymyxin B (3–10 mg/kg) improves survival in a dose-dependent manner and reduces bacterial loads within 6 hours post-infection (Sardar et al., 2025, DOI).
• Polymyxin B inhibits LPS–TLR4 signaling, thereby modulating host immune responses to Gram-negative bacteria and influencing immunotherapy outcomes (Sardar et al., 2025, DOI).
• The compound is ≥95% pure, has a molecular weight of 1301.6, and is soluble up to 2 mg/mL in PBS (pH 7.2), with optimal storage at −20°C (APExBIO, product page).

Applications, Limits & Misconceptions

Polymyxin B (sulfate) is extensively deployed in infection models, sepsis research, and immune signaling studies. It is the agent of choice for neutralizing LPS in dendritic cell assays, distinguishing cell-intrinsic effects from those mediated by bacterial products (related article; this review provides updated mechanistic insights and extended benchmarks in immunomodulation). The compound is also used in preclinical models of bacteremia and urinary tract infections, and in workflow optimization for Gram-negative infection studies (related article; this article clarifies technical troubleshooting and solution stability, which are further detailed here).

Common Pitfalls or Misconceptions

• Polymyxin B (sulfate) is ineffective against most Gram-positive bacteria and fungi at concentrations typically used for Gram-negative infection models (APExBIO).
• Systemic use is limited by nephrotoxicity and neurotoxicity, especially with repeated or high-dose exposure (Sardar et al., 2025, DOI).
• It does not neutralize all forms of LPS equivalently; penta- and tetra-acylated LPS variants may evade neutralization (Sardar et al., 2025, DOI).
• Prolonged storage or repeated freeze-thaw cycles reduce solution stability and activity—solutions should be freshly prepared and used promptly (APExBIO).
• Polymyxin B may interfere with certain cell-based assays by directly affecting eukaryotic membrane integrity at high concentrations.

Workflow Integration & Parameters

For in vitro infection models, Polymyxin B (sulfate) should be reconstituted at up to 2 mg/mL in PBS (pH 7.2). For dendritic cell maturation assays, 1–2 μg/mL is typical, with 24–48 h exposure. In animal models of bacteremia or sepsis, doses between 3–10 mg/kg (intraperitoneally) are used for efficacy benchmarking (Sardar et al., 2025). All solutions should be freshly prepared and stored at −20°C for short-term use. APExBIO's C3090 product guarantees ≥95% purity, ensuring reproducibility and minimal batch-to-batch variability (Polymyxin B (sulfate) from APExBIO).

Conclusion & Outlook

Polymyxin B (sulfate) remains a cornerstone for research and clinical management of multidrug-resistant Gram-negative infections. Its dual utility as a bactericidal agent and a tool for dissecting LPS-mediated immune responses positions it at the intersection of microbiology, immunology, and translational medicine. Future work will refine dosing and delivery to minimize toxicity while maximizing efficacy, and further clarify its role in modulating host-pathogen interactions, especially in the context of immunotherapy. For standardized, high-quality applications, APExBIO provides validated Polymyxin B (sulfate) (C3090) for robust experimental workflows.